Correlation Between CRISPR Therapeutics and Broadcom

Can any of the company-specific risk be diversified away by investing in both CRISPR Therapeutics and Broadcom at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining CRISPR Therapeutics and Broadcom into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between CRISPR Therapeutics AG and Broadcom, you can compare the effects of market volatilities on CRISPR Therapeutics and Broadcom and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in CRISPR Therapeutics with a short position of Broadcom. Check out your portfolio center. Please also check ongoing floating volatility patterns of CRISPR Therapeutics and Broadcom.

Diversification Opportunities for CRISPR Therapeutics and Broadcom

-0.37

Correlation Coefficient

CRISPR Therapeutics  Broadcom

Very good diversification

The 3 months correlation between CRISPR and Broadcom is -0.37. Overlapping area represents the amount of risk that can be diversified away by holding CRISPR Therapeutics AG and Broadcom in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Broadcom and CRISPR Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on CRISPR Therapeutics AG are associated (or correlated) with Broadcom. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Broadcom has no effect on the direction of CRISPR Therapeutics i.e., CRISPR Therapeutics and Broadcom go up and down completely randomly.

Pair Corralation between CRISPR Therapeutics and Broadcom

Assuming the 90 days trading horizon CRISPR Therapeutics AG is expected to under-perform the Broadcom. But the stock apears to be less risky and, when comparing its historical volatility, CRISPR Therapeutics AG is 1.57 times less risky than Broadcom. The stock trades about -0.01 of its potential returns per unit of risk. The Broadcom is currently generating about 0.17 of returns per unit of risk over similar time horizon. If you would invest  1,376  in Broadcom on October 4, 2024 and sell it today you would earn a total of  674.00  from holding Broadcom or generate 48.98% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	98.33%
Values	Daily Returns

CRISPR Therapeutics AG  vs.  Broadcom

CRISPR Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days CRISPR Therapeutics AG has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, CRISPR Therapeutics is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Broadcom

Risk-Adjusted Performance

13 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Broadcom are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak technical and fundamental indicators, Broadcom sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with CRISPR Therapeutics and Broadcom

The main advantage of trading using opposite CRISPR Therapeutics and Broadcom positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if CRISPR Therapeutics position performs unexpectedly, Broadcom can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Broadcom will offset losses from the drop in Broadcom's long position.

The idea behind CRISPR Therapeutics AG and Broadcom pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.